Billing details

Your order

Product Subtotal
Do faster drug approvals increase safety risks? Evidence from Canada and Europe 2003-2012.  × 1 $10.00
Les coûts potentiels découlant de la substitution thérapeutique des médicaments au Québec.  × 1 $10.00
Comparing access to new drugs in Canada's public drug plans. 2014 Annual Report.  × 1 $10.00
Adapting the Safe Consumption Site Model for Patient-Procured MDMA  × 1 $40.00
Private versus public drug coverage in Canada. 2014 Annual Report.  × 1 $10.00
Subtotal $80.00
HST (13%) $10.40
Total $90.40
  • Pay via PayPal.

Your personal data will be used to process your order, support your experience throughout this website, and for other purposes described in our privacy policy.